FDA does U-turn, will review Moderna's mRNA flu shot after shocking rejection

Here's something that caught my attention — the FDA did a complete 180 on Moderna’s mRNA flu vaccine. Just last week, they shockingly refused to even review it, a move that seemed driven more by politics than science, according to Beth Mole writing in Technology. The decision was made by Vinay Prasad, a Trump-era appointee, who overruled agency scientists and a top official, which raised eyebrows across the industry. But here’s where it gets interesting: Moderna didn’t just give up. They held a formal meeting with the FDA, proposed a new way to navigate the approval process, and now, the agency has agreed to review their vaccine. That’s a big shift, especially after such a controversial rejection. As Beth Mole reports, this turnaround shows how regulatory paths can still change — especially when companies push back with new data and proposals. So, keep an eye — this could set a new precedent for vaccine approvals moving forward.